Mind Cure’s latest addition to its Scientific Advisory Board is a noted expert in psychedelic medicine, published researcher, and professor of pharmacology.

Mydecine’s new patent application may lead to a way to derive the medicinal benefits of psilocybin at lower doses.

The mental healthcare industry is ripe for innovation.  And companies like Mind Cure (CSE: MCUR), which recently completed its IPO, are set to lead the way.

This is Mind Cure’s third high-profile addition to its Scientific Advisory Board in the last week.

Publicly traded multistate marijuana operators appear to be in better financial health than they were at the beginning of the year, but many have shed operations in potentially lucrative markets to bolster their balance sheets.